1 / 42

Welcome Ask The Experts March 24-27, 2007 New Orleans, LA

Welcome Ask The Experts March 24-27, 2007 New Orleans, LA. Dr. Germano Di Sciascio. ARMYDA-ACS: Atorvastatin Pretreatment Improves Outcome in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.

Samuel
Download Presentation

Welcome Ask The Experts March 24-27, 2007 New Orleans, LA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Welcome Ask The Experts March 24-27, 2007 New Orleans, LA

  2. Dr. GermanoDi Sciascio ARMYDA-ACS: Atorvastatin Pretreatment Improves Outcome in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

  3. ARMYDA-ACS (Atorvastatin for Reduction of MYocardial Damage during Angioplasty- Acute Coronary Syndromes ) trial Multicenter, randomized, double blind, prospective study evaluating effects on outcome of atorvastatin pre-treatment in patients with Acute Coronary Syndromes undergoing early PCI Chairman of the Study: Germano Di Sciascio Principal Investigators:Giuseppe Patti, Vincenzo Pasceri, Rino Sardella, Giuseppe Colonna Investigators: Antonio Montinaro, Marco Miglionico, Luigi Fischetti, Andrea D’Ambrosio, Annunziata Nusca, Giordano Dicuonzo, Bibi NGuyen, Laura Gatto, Fabio Mangiacapra

  4. BACKGROUND • The original ARMYDA trial demostrated that 7-day pretreatment with atorvastatin (40 mg/day) confers 81% risk reduction of peri-procedural MI in patients with Stable Angina undergoing elective PCI Primary end point: Incidence of MI 18 P=0.025 MI (%) 5 Pasceri V, Patti G, Di Sciascio G, et al. Circulation 2004;110:674-678

  5. BACKGROUND • Efficacy of statin pretreatment in patients with ACS undergoing early PCI has not characterized • An observational study on 119 pts has suggested that patients with ACS who were already receiving statins at the time of intervention have a lower incidence of peri-procedural myonecrosis; however, patients were treated with different types of statins, variable doses and unknown duration of previous treatment, and those findings have not been validated in a randomized trial. Chang SM, et al. Cathet Cardiovasc Interv 2004

  6. ARMYDA-ACS trial • Inclusion criteria: • NSTE-ACS undergoing early angiography (<48 hrs) Exclusion criteria: • STEMI • ACS with high risk features warranting emergency angiography • Previous or current statin therapy • LVEF <30% • Contraindications to statins (liver or muscle disease) • Severe renal failure (creatininine >3 mg/dl)

  7. ARMYDA-ACS trial: Study design 580 pts excluded for: - 451 statin therapy - 41 emergency angiography - 43 LVEF <30% - 30 contraindications to statins - 15 severe renal failure 20 pts excluded for indication to: - medical therapy (N=8) - bypass surgery (N=12) 30 days Atorvastatin 80 mg 12 hrs pre-angio; further 40 mg 2 hrs before N=96 771 pts with NSTE-ACS sent to early coronary angiography (<48 hours) Jan ’05 - Dec ‘06 Randomization (N=191) PCI atorvastatin N=86 Primary combined end point: 30-day death, MI, TVR Coronary angiography atorvast PCI placebo N=85 Placebo 12 hrs pre-angio; further dose 2 hrs before N=95 2nd and 3rd blood samples (8 and 24 hrs post-PCI) 1st blood sample (pre-PCI) CK-MB, troponin-I, myoglobin, CRP

  8. ARMYDA-ACS trial: Study end points • Primary end point: • Incidence of major adverse cardiac events (MACE: death, MI, TVR) from the procedure up to 30 days • MI definition: • - If normal baseline levels of CK-MB: post-procedural increase of CK-MB >2 times above UNL, according to the consensus statement of the Joint ESC/ACC Committee for the Redefinition of Myocardial Infarction for clinical trials on coronary intervention. • - If elevated baseline levels of CK-MB: subsequent rise of >2 times in CK-MB from baseline value • Secondary end points: • Any post-procedural increase of markers of myocardial injury above UNL (CK-MB, troponin-I, myoglobin) • Post-PCI variations from baseline of CRP levels in the 2 arms

  9. ARMYDA-ACS: Main Clinical Features in the Atorvastatin and Placebo Groups

  10. ARMYDA-ACS:Procedural Features in the Atorvastatin and Placebo Groups

  11. ARMYDA-ACS trial Composite primary end-point (30-day death, MI, TVR) % 17 P=0.01 5

  12. ARMYDA-ACS Individual and Combined Outcome Measures of the Primary End Point at 30 days 14/85 (17%) % 13/85 (15%) P=0.01 P=0.04 4/86 (5%) 4/86 (5%) 1/85 (2%) Composite Primary End Point

  13. ARMYDA-ACS: Secondary end point Cardiac markers elevations 1-3 times >3 times P=0.028 P=0.002 Creatine kinase-MB (%) Troponin-I (%)

  14. ARMYDA-ACS: Secondary end point Post-PCI percent increase of CRP levels from baseline 147 P=0.01 % 63

  15. ARMYDA-ACS: Actuarial Survival curves Atorvastatin Placebo 100 80 60 P=0.01 MACE-free survival (%) 40 20 0 1 2 3 7 14 21 30 Days after PCI

  16. ARMYDA-ACS: Odds Ratio for 30-day MACE 1 2 0 3 4 5 NSTEMI 1.3 (0.36-4.8) LVEF <40% 3.6 (1.1-10.4) IIb/IIIa inhibitors 4.2 (2.1-12.2) Beta-blockers 0.75 (0.44-2.8) Ace-inhibitors 0.88 (0.59-3.9) Atorvastatin 0.12 (0.05-0.50)

  17. ARMYDA-ACS: CONCLUSIONS • The ARMYDA-ACS trial indicates that even a short-term atorvastatin pretreatment prior to PCI may improve outcome in patients with Unstable Angina and NSTEMI. • This benefit is mostly driven by a reduction of peri-procedural MI (70% risk reduction) • Lipid-independent pleiotropic actions of atorvastatin may explain such effect • These findings may support the indication of “upstream” administration of high dose statins in patients with Acute Coronary Syndromes treated with early invasive strategy

  18. * P<0.05 Possible mechanisms of the clinical benefit: Improvement of endothelial function N=27 pts with stable angina randomized to placebo or pravastatin (single dose of 40 mg). At 24 hrs, significant attenuation of acetylcholine-mediated vasoconstriction Wassmann S, et al. Circ Res 2003

  19. Possible mechanisms of the clinical benefit: Vasodilation of coronary microvessels Coronary flow velocity reserve (hyperemic/basal peak diastolic velocity) N=32 pts without CAD randomized to placebo or atorvastatin (single dose of 40 mg) transthoracic doppler evaluation of LAD (baseline and 1 hr) P<0.01 Hinoi T, et al. Am J Cardiol 2005

  20. Possible mechanisms of the clinical benefit: Antithrombotic effects N=30 hypercholesterolemic pts randomized to diet or atorvastatin (10 mg/d) for 3 days Prothrombin fragment F1+2 (nM) PLT CD40L expression (AU) P<0.01 45+12 46+15 43+15 P<0.05 2+1 2+1 2+1 32+6 1.4+0.4 Sanguigni V, et al. Circulation 2005

  21. Possible mechanisms of the clinical benefit: Attenuation of endothelial activation ARMYDA-CAMs RESULTS P=0.0008 P=0.0001 78 100 P=0.33 75 P=0.0001 80 P=0.55 59 60 P=0.20 60 Post-procedural 24-hour % increase from baseline 42 45 E-selectin peak levels (ng/mL) 30 40 30 20 15 0 0 No Damage Damage No Damage Damage ICAM-1 E-selectin VCAM-1 Atorvastatin Placebo Patti G et al. JACC 2006;48:1560

  22. UNRESOLVED ISSUES • ARMYDA-ACS results cannot be directly extrapolated to - pts with ST-segment elevation myocardial infarction - pts with ACS undergoing emergency revascularization - pts with ACS treated medically or receiving bypass surgery • It is unclear whether patients on chronic statin treatment may have a clinical benefit similar to that observed with acute administration. Indeed, in a rat model of ischemia/reperfusion, the acute protective effect of atorvastatin on myocardial injury wanes with a longer treatment, but this effect can be recaptured by a “reloading” given immediately before ischemia/reperfusion Supplementary dose given a few hours before ischemia/reperfusion Mensah K et al – JACC 2005

  23. ARMYDA-ACS: Main Clinical Features in the Atorvastatin and Placebo Groups

  24. Possible mechanisms of the clinical benefit: Direct myocardial protection Ischemia/reperfusion on isolated perfused mouse hearts Effect prevented by an inhibitor of PI3K Bell RM, et al. JACC 2003

  25. ARMYDA-ACS: Procedural Features in the Atorvastatin and Placebo Groups

  26. Primary end point RESULTS Post-PCI incidence of myocardial infarction (CK-MB> 2 times UNL) 30 P=0.025 18 20 CK-MB (%) 10 5 0 Placebo Atorvastatin

  27. ARMYDA-ACS trial 30 days Atorvastatin 80 mg the day before and 40 mg 4 to 6 hrs before PCI N=76 • Patients with • NSTE ACS • and • Indication to • PCI, • “Statin-naive” Atorvastatin group Primary endpoint: 30-day occurrence of death, MI*, TVR Randomization PCI Placebo group Placebo the day before and 4 to 6 hrs before PCI N=77 1° blood sample (before PCI) 2° and 3° blood samples (8 and 24 hrs after PCI) • MI= CK-MB >2 times UNL or • >2 times the baseline value (if increased) CK-MB, troponin I, myoglobin, CRP

  28. ARMYDA-CAMs RESULTS P=0.0001 100 P=0.0001 80 P=0.20 60 Post-procedural 24-hour % increase from baseline 40 20 0 ICAM-1 E-selectin VCAM-1 Atorvastatin Placebo Patti G, Di Sciascio G; JACC 2006:48:1560-6

  29. ARMYDA-ACS trial Secondary endpoint: Post-procedural CK-MB and Tn-I elevation above UNL Data on the first 153 pts (Sept ’06) 56 P=0.025 P=0.040 49 % 38 30 CK-Mb Tn-I

  30. Improving outcome after PCI by reducing peri-procedural MI The ARMYDA trials 18% 6% 5% 5% ARMYDA-1 No statin No 600 mg clop. ARMYDA-1 Atorvastatin No 600 mg clop. ARMYDA-2 Statin 600 mg clop. ARMYDA-ACS Atorvastatin 600 mg clop. Pts with CSA or ACS Pts with CSA Pts with ACS

  31. ARMYDA trial - Secondary end point: Incidence of any post-PCI increase of CK-MB and Troponin-I above UNL 50 40 P=0.001 40 P=0.006 30 30 CK-MB (%) Troponin-I (%) 20 20 10 10 0 0 Atorvastatin Placebo Atorvastatin Placebo > 1 time 2-5 times >5 times UNL Pasceri V, Patti G, Di Sciascio G, et al. Circulation 2004

  32. Final results of the ARMYDA-ACS (Atorvastatin for Reduction of MYocardial Damage during Angioplasty- Acute Coronary Syndromes) trial

  33. Individual and Combined Outcome Measures of the Primary End Point at 30 days in the Atorvastatin and Placebo Groups

  34. ARMYDA-ACS (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Acute Coronary Syndromes) trial Randomized, placebo-controlled, double blind, prospective trial, evaluating whether pretreatment with atorvastatin load influences outcome in patients with acute coronary syndromes undergoing early PCI Chairman:Germano Di Sciascio Principal investigator: Giuseppe Patti Investigators: Vincenzo Pasceri,Giuseppe Colonna,Gennaro Sardella, Marco Miglionico, Dionigi Fischetti, Andrea D’Ambrosio, Bibi Nguyen, Antonio Montinaro, Annunziata Nusca

  35. Question & Answer

  36. Thank You! Please make sure to hand in your evaluation and pick up a ClinicalTrialResults.org flash drive

More Related